Phase 2 N=7 TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Metastatic Ovarian Cancer
Primary: Number of Participants With Reported Adverse Events by Type — 3; 3; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
Squamous Cell Carcinoma of Head and Neck
Primary: Percent of Eligible Participants Who Accrue to NDURE — 15 Participants
N/A N=183 Study of Uterine Prolapse Procedures - Randomized Trial
Uterovaginal Prolapse
Primary: Cumulative Failure — 78; 69; 9; 16 Participants
Phase 3 N=697 Tanezumab in Osteoarthritis of the Knee
Arthritis · Osteoarthritis
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)…
Phase 2 N=30 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Blasts 10 Percent or More of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia-2 · High Grade Malignant Neoplasm
Primary: Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant — 9; 21 Participants
N/A N=20 Modified AutoSet Device vs Existing AutoSet Device, the Assessment of Efficacy and Subjective Comfort of the Treatment.
Sleep Apnea
Primary: Apnoea-Hypopnoea Index (AHI) — 1.69; 1.73 Events/Hour
Phase 2 N=12 Ketamine and Prolonged Exposure in PTSD
Post-traumatic Stress Disorder
Primary: Change in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms — 15.3 units on a scale
Phase 3 N=402 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Phase 2 N=10 Aurinia Early Urinary Protein Reduction Predicts Response
Lupus Nephritis
Primary: Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR) — 7 Participants
Phase 1 N=6 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · Indolent Non-Hodgkin Lymphoma · Follicular Lymphoma
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure — 66.7; 16.7…
Phase 2 N=29 Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
Head and Neck Cancer
Primary: 20 Week Progression Free Survival Rate — 0.90 proportion of participants
Phase 1 N=30 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Phase 3 N=222 SpaceOAR System Pivotal Study
Prostate Cancer
Primary: Number of Subjects Achieving a Reduction of 25% or Greater in Percent Volume of the Rectum Receiving at Least 70 Gy Measured From CT Scans Acquired Pre and Post SpaceOAR…
N/A N=535 A Stepped Care Intervention to Reduce Disparities in Mental Health Services Among Cancer Patients and Caregivers
Cancer, Lung · Cancer, Head and Neck
Primary: Symptoms of Depression-Patients — 15.3; 13.2 score on a scale — p=0.0057
Phase 4 N=24 Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses
Healthy Human Volunteers
Primary: Tolerance to Cutaneous Electrical Current — 26.6; 27.1 mA